We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current IBRX market cap is 4.2B. The company's latest EPS is USD -0.8734 and P/E is -37.20.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 360k | 41k | 82k | 139k | 40k |
| Operating Income | -113.92M | -89.1M | -81.39M | -85.39M | -95.2M |
| Net Income | -116.34M | -137.88M | -95.58M | -233.39M | -134.11M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 43k | 111k | 934k | 240k | 622k |
| Operating Income | -67.81M | -91.63M | -330.28M | -363.41M | -369.8M |
| Net Income | -65.79M | -92.38M | -346.79M | -416.57M | -583.2M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 343.4M | 291.23M | 432.42M | 504.45M | 400.68M |
| Total Liabilities | 875.12M | 936.41M | 843.06M | 1.09B | 1.09B |
| Total Equity | -531.72M | -645.18M | -410.65M | -585.94M | -690.98M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 143.12M | 151.86M | 468.91M | 362.36M | 504.45M |
| Total Liabilities | 22.44M | 34.47M | 712.82M | 812.18M | 1.09B |
| Total Equity | 120.68M | 117.39M | -243.91M | -449.82M | -585.94M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -84.31M | -164.08M | -251.49M | -366.76M | -106.98M |
| Investing | -8.48M | -17.09M | -32.72M | -30.47M | -35.62M |
| Financing | 76.89M | 120.3M | 357.8M | 558.34M | 10.23M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -61.36M | -70.45M | -274.42M | -337.51M | -366.76M |
| Investing | 21.46M | -20.59M | -84.89M | 27.3M | -30.47M |
| Financing | 38.59M | 86.98M | 505.44M | 233.61M | 558.34M |
| Market Cap | 4.2B |
| Price to Earnings Ratio | -37.20 |
| Price to Sales Ratio | 36.1k |
| Price to Cash Ratio | 81.72 |
| Price to Book Ratio | -37.02 |
| Dividend Yield | - |
| Shares Outstanding | 667.71M |
| Average Volume (1 week) | 3.37M |
| Average Volume (1 Month) | 4.33M |
| 52 Week Change | 124.82% |
| 52 Week High | 10.53 |
| 52 Week Low | 1.25 |
| Spread (Intraday) | 0.01 (0.16%) |
| Company Name | ImmunityBio Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.immunitybio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
